Morgan Stanley Institutional Vitality Portfolio R6 (MSVOX)
5.44
+0.04
(+0.74%)
USD |
Jul 08 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 0.90% | 1.889M | 0.31% | 19.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -67377.00 | -8.76% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. Under normal market conditions, the Adviser seeks to invest primarily in securities of companies located in the United States that are principally engaged in the discovery, development, production, or distribution of products or services related to advances in healthcare. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Morgan Stanley |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
7
-855.68M
Peer Group Low
14.44M
Peer Group High
1 Year
% Rank:
9
-67377.00
-2.481B
Peer Group Low
10.00M
Peer Group High
3 Months
% Rank:
6
-1.293B
Peer Group Low
15.94M
Peer Group High
3 Years
% Rank:
15
-6.960B
Peer Group Low
87.29M
Peer Group High
6 Months
% Rank:
8
-1.663B
Peer Group Low
10.00M
Peer Group High
5 Years
% Rank:
17
-6.729B
Peer Group Low
4.689B
Peer Group High
YTD
% Rank:
8
-1.663B
Peer Group Low
10.00M
Peer Group High
10 Years
% Rank:
29
-12.22B
Peer Group Low
5.565B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of July 09, 2025.
Asset Allocation
As of March 31, 2025.
| Type | % Net |
|---|---|
| Cash | 0.00% |
| Stock | 99.43% |
| Bond | 0.57% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Eli Lilly and Co | 9.02% | 777.66 | 0.62% |
| argenx SE | 7.67% | 538.64 | -1.36% |
| UnitedHealth Group Inc | 6.11% | 307.70 | 1.31% |
| Vertex Pharmaceuticals Inc | 5.27% | 466.36 | 1.51% |
| Exact Sciences Corp | 5.12% | 53.54 | 2.02% |
| Alnylam Pharmaceuticals Inc | 4.86% | 317.50 | -2.05% |
| Thermo Fisher Scientific Inc | 4.84% | 426.17 | 1.78% |
| Intuitive Surgical Inc | 4.69% | 527.30 | -1.39% |
| Ascendis Pharma AS | 4.19% | 168.17 | -4.44% |
| Zoetis Inc | 3.55% | 157.80 | 0.48% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | -- |
| Administration Fee | 27.00% |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 10.00M None |
| Minimum Subsequent Investment | 0.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital appreciation. Under normal market conditions, the Adviser seeks to invest primarily in securities of companies located in the United States that are principally engaged in the discovery, development, production, or distribution of products or services related to advances in healthcare. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Morgan Stanley |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (7-8-25) | 0.14% |
| 30-Day SEC Yield (4-30-22) | 0.00% |
| 7-Day SEC Yield | -- |
| Stock | |
| Weighted Average PE Ratio | 45.29 |
| Weighted Average Price to Sales Ratio | 11.13 |
| Weighted Average Price to Book Ratio | 9.042 |
| Weighted Median ROE | 2.37% |
| Weighted Median ROA | -6.40% |
| ROI (TTM) | -8.31% |
| Return on Investment (TTM) | -8.31% |
| Earning Yield | 0.0248 |
| LT Debt / Shareholders Equity | 1.879 |
As of March 31, 2025
Growth Metrics
| EPS Growth (1Y) | 9.73% |
| EPS Growth (3Y) | 10.78% |
| EPS Growth (5Y) | 21.29% |
| Sales Growth (1Y) | 20.31% |
| Sales Growth (3Y) | 22.98% |
| Sales Growth (5Y) | 31.38% |
| Sales per Share Growth (1Y) | 14.22% |
| Sales per Share Growth (3Y) | 14.82% |
| Operating Cash Flow - Growth Ratge (3Y) | 6.06% |
As of March 31, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:MSVOX", "name") |
| Broad Asset Class: =YCI("M:MSVOX", "broad_asset_class") |
| Broad Category: =YCI("M:MSVOX", "broad_category_group") |
| Prospectus Objective: =YCI("M:MSVOX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |